Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior-Reference-Cited by-同舟云学术

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior

Published:2019-06-21 Issue:8 Volume:16 Page:3524-3533
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Dekempeneer Yana¹²^ORCID,Bäck Tom³,Aneheim Emma³,Jensen Holger⁴,Puttemans Janik¹,Xavier Catarina¹,Keyaerts Marleen¹⁵,Palm Stig³,Albertsson Per³,Lahoutte Tony¹⁵,Caveliers Vicky¹⁵,Lindegren Sture³,D’Huyvetter Matthias¹

Affiliation:

1. In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels 1090, Belgium

2. Institute for Nuclear Materials Science, Belgian Nuclear Research Center (SCK·CEN), Mol 2400, Belgium

3. Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-413 45, Sweden

4. The PET and Cyclotron Unit, KF3982, Copenhagen University Hospital, Copenhagen 2100, Denmark

5. Nuclear Medicine Department, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels 1090, Belgium

Funder

Fonds Wetenschappelijk Onderzoek

European Organisation for Research and Treatment of Cancer

Kom op tegen Kanker

Studiecentrum voor Kernenergie

Flemish Cancer Society

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.9b00354

Reference38 articles.

1. The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond

2. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

3. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

4. Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study

5. Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

2. Development of a Neopentyl ²¹¹At‐Labeled Activated Ester Providing In Vivo Stable ²¹¹At‐Labeled Antibodies for Targeted Alpha Therapy;ChemMedChem;2024-08-08

3. ²¹¹At-Labeled Nanoscale Polydopamine Decorated with FAPI for Synergistic Targeted-Alpha Therapy and Photothermal Therapy of Glioma;ACS Applied Nano Materials;2024-03-21

4. In vivo stability of ²¹¹At-radiopharmaceuticals: on the impact of halogen bond formation;RSC Medicinal Chemistry;2024

5. Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery;Molecular Imaging and Biology;2023-10-16